Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Growth versus Fixed Mindset

Growth versus Fixed Mindset

Carol Dweck introduced the term mindset to describe individuals' beliefs about their intellectual and personal capabilities. These beliefs significantly influence psychological processes such as motivation, goal-setting, and perseverance, ultimately shaping academic and life outcomes. Individuals generally possess one of two mindsets- a fixed or a growth mindset—each promoting different responses to success, failure, and challenge.Fixed vs. Growth MindsetA fixed mindset assumes that one's...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single-molecule imaging reveals RNA polymerase II dynamics and TAF1-dependent promoter-proximal pause release.

Nature communications·2026

Same author

Transitory enhancement of GATA2 chromatin engagement during early erythroid differentiation.

bioRxiv : the preprint server for biology·2026

Same author

Chromatin Engagement and Transcriptional Activity of the ZNF217 Exon 4-Skipping Isoform Are Associated with Breast Cancer Aggressiveness and Bone Metastasis.

Cancers·2026

Same author

Gene Expression Imaging in Hematopoiesis.

Journal of molecular biology·2025

Same author

NMNAT1 Binding at Promoters and Enhancers Couples NAD <sup>+</sup> Synthesis to RNA Polymerase II Engagement.

bioRxiv : the preprint server for biology·2025

Same author

Dynamic transcription pre-initiation complex assembly governs initiation efficiency.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Development of New Therapeutic Applications Using Microfluidics

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

Drug discovery and development tomorrow -- changing the mindset.

Robert A Coleman¹

¹Consultant, Falmouth, UK. robt.coleman@btinternet.com

Alternatives to Laboratory Animals : ATLA

|October 8, 2009

Summary

A new study proposes using human-based tests to evaluate drug safety and efficacy, moving away from animal models. This approach aims to improve pharmaceutical R&D productivity and regulatory decision-making.

Area of Science:

Pharmacology
Toxicology
Biomedical Research

Background:

Current drug discovery and development paradigms face significant challenges.
Over-reliance on animal models in pharmaceutical research may hinder productivity and safety outcomes.
A shift towards human-based testing requires evidence of improved research and development (R&D) productivity.

Purpose of the Study:

To evaluate the efficiency of human-based test methods in identifying drug safety and efficacy profiles.
To compare the performance of human-based tests against traditional animal-based methods used in drug development.
To provide evidence supporting the adoption of human-based biological data in regulatory submissions.

Main Methods:

A study involving a range of approved drugs with known safety and/or efficacy limitations.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Related Experiment Videos

Last Updated: Jun 19, 2026

Development of New Therapeutic Applications Using Microfluidics

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Utilizing a battery of human-based test methods to assess compound profiles.

Comparing the predictive accuracy of human-based methods with historical animal-based data.

Main Results:

The study aims to determine if human-based tests are more reliable than animal models.
Expected outcomes will highlight the potential for improved identification of drug safety and efficacy.
Data will inform regulatory authorities and the pharmaceutical industry on the utility of human biological test data.

Conclusions:

Human-based testing offers a promising alternative to traditional animal models in drug development.
Successful implementation requires addressing logistical challenges in acquiring human biomaterials.
Regulatory bodies and the pharmaceutical industry must consider the role of human biological data for future R&D.